<!DOCTYPE html>

<html lang="en">
<head>
<meta charset="utf-8"/>
<title>article93</title>
<style>
        body {
            font-family: Arial, sans-serif;
            margin: 0;
            padding: 0;
            background-color: #f3f3f3;
        }
        .container {
            max-width: 800px;
            margin: auto;
            background: #fff;
            padding: 20px;
            box-shadow: 0 0 10px rgba(0, 0, 0, 0.1);
        }
        h1, h2 {
            color: #333;
        }
        p {
            line-height: 1.6;
        }
        a {
            text-decoration: none;
            color: #5a5a5a;
        }
        a:hover {
            color: #000;
        }
    </style>
</head>
<body>
<div class="container"><p><a href="../index_gpt.html">Back to Index</a></p><li><a href="https://www.wikijournalclub.org/wiki/RE-DUAL" style="display:block; margin-bottom:10px;">RE-DUAL Original</a></li>
<h2><strong>RE-DUAL</strong></h2>
<div class="container">
<h2><strong></strong></h2>
<div class="container">
<div class="container">
<h2><strong></strong></h2>
<h2><strong></strong></h2>

    "Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation".The New England Journal of Medicine. 2017. 377(16):1513-1524.PubMed•Full text•PDF<br/>
<br/>
<h2><strong>Contents</strong></h2><br/>
<br/>
1Clinical Question<br/>
2Bottom Line<br/>
3Major Points<br/>
4Guidelines<br/>
5Design<br/>
6Population<br/>
6.1Inclusion Criteria<br/>
6.2Exclusion Criteria<br/>
6.3Baseline Characteristics<br/>
7Interventions<br/>
8Outcomes<br/>
8.1Primary Outcome<br/>
8.2Secondary Outcomes<br/>
9Criticisms<br/>
10Funding<br/>
11Further Reading<br/>
<br/>
<br/>
<h2><strong>Clinical Question</strong></h2><br/>
<br/>
In patients with atrial fibrillation who have undergone percutaneous coronary intervention (PCI), does dual antithrombotic therapy with dabigatran reduce the risk of bleeding compared to triple therapy with warfarin?<br/>
<br/>
<h2><strong>Bottom Line</strong></h2><br/>
<br/>
Dual antithrombotic therapy with dabigatran plus a P2Y12 inhibitor (clopidogrel or ticagrelor) after PCI in patients with atrial fibrillation was associated with a lower risk of bleeding events compared to triple therapy with warfarin, a P2Y12 inhibitor, and aspirin. Dual therapy with dabigatran was also noninferior to triple therapy with warfarin with respect to risk of thromboembolic events.<br/>
<br/>
<h2><strong>Major Points</strong></h2><br/>
<br/><br/>
<br/>
<h2><strong>Guidelines</strong></h2><br/>
<br/><br/>
<br/>
<h2><strong>Design</strong></h2><br/>
<br/>
- Multicenter, randomized, open-label trial.<br/>
- N=2,725 patients with atrial fibrillation who had undergone PCI.<br/>
- Intervention groups:<br/>
  - Dual therapy: dabigatran (110 mg or 150 mg twice daily) + P2Y12 inhibitor (clopidogrel or ticagrelor).<br/>
  - Triple therapy: warfarin + a P2Y12 inhibitor + aspirin (stopped after 1 to 3 months).<br/>
- Mean follow-up of 14 months.<br/>
- Primary efficacy analysis: intention-to-treat.<br/>
<br/>
<h2><strong>Population</strong></h2><br/>
<br/>
Inclusion Criteria<br/>
<br/>
- Adults ≥18 years with nonvalvular atrial fibrillation.<br/>
- Successful PCI with a bare-metal or drug-eluting stent within the previous 120 hours.<br/>
<br/>
Exclusion Criteria<br/>
<br/>
- Bioprosthetic or mechanical heart valves, severe renal insufficiency, major coexisting conditions.<br/>
<br/>
Baseline Characteristics<br/>
<br/>
- Mean age: 70.8 years.<br/>
- Acute coronary syndrome indication for 50.5% of patients.<br/>
- Drug-eluting stents used in 82.6%.<br/>
<br/>
<h2><strong>Interventions</strong></h2><br/>
<br/>
- Randomization to dual therapy with dabigatran or triple therapy with warfarin.<br/>
- Duration of aspirin component in triple therapy: 1 month for bare-metal stent, 3 months for drug-eluting stent.<br/>
<br/>
<h2><strong>Outcomes</strong></h2><br/>
<br/>
Primary Outcome<br/>
<br/>
- Lower incidence of major or clinically relevant nonmajor bleeding with dual therapy (both dabigatran doses) compared to triple therapy.<br/>
<br/>
Secondary Outcomes<br/>
<br/>
- Dual therapy was noninferior to triple therapy regarding thromboembolic events, death, or unplanned revascularization.<br/>
- No significant difference in serious adverse events between the groups.<br/>
<br/>
<h2><strong>Criticisms</strong></h2><br/>
<br/>
- The original protocol called for more patients than were enrolled, potentially limiting power to examine individual efficacy according to dabigatran dose.<br/>
- Noninferiority margin was based on previous atrial fibrillation studies for a dissimilar endpoint.<br/>
- Contributions of aspirin omission and oral anticoagulant type regarding outcome differences between dual and triple therapy could only be speculated.<br/>
<br/>
<h2><strong>Funding</strong></h2><br/>
<br/>
Funded by Boehringer Ingelheim.<br/>
<br/>
<h2><strong>Further Reading</strong></h2><br/>
<br/>
Please refer to the New England Journal of Medicine article and included references for more detailed information.
    <p></p>
</div>
</div>
</div>
</div>
</body>
</html>
